Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Affymax Inc. stock logo
AFFY
Affymax
$0.00
$0.00
$0.00
$0.00
N/A7.342,186 shsN/A
AOBI
American Oriental Bioengineering
$0.00
$0.00
$0.00
$0.00
N/A7.285 shsN/A
AOLS
Aeolus Pharmaceuticals
$0.00
$0.00
$0.01
N/A1.2835 shsN/A
89BIO stock logo
ETNB
89BIO
$10.14
+0.4%
$9.26
$4.16
$11.84
$1.48B1.281.52 million shs1.94 million shs
MYRX
Myrexis
$0.00
$0.00
$0.00
$0.01
N/A0.6321 shsN/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Affymax Inc. stock logo
AFFY
Affymax
0.00%0.00%+700.00%-66.67%+14.29%
AOBI
American Oriental Bioengineering
0.00%0.00%0.00%0.00%0.00%
AOLS
Aeolus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
89BIO stock logo
ETNB
89BIO
0.00%+2.84%-1.07%+84.70%+34.84%
MYRX
Myrexis
0.00%0.00%+100.00%-97.14%-96.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/AN/AN/AN/A
AOBI
American Oriental Bioengineering
N/AN/AN/AN/AN/AN/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
89BIO stock logo
ETNB
89BIO
1.5652 of 5 stars
3.51.00.00.01.10.80.6
MYRX
Myrexis
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Affymax Inc. stock logo
AFFY
Affymax
0.00
N/AN/AN/A
AOBI
American Oriental Bioengineering
0.00
N/AN/AN/A
AOLS
Aeolus Pharmaceuticals
0.00
N/AN/AN/A
89BIO stock logo
ETNB
89BIO
3.00
Buy$26.43160.64% Upside
MYRX
Myrexis
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MYRX, ETNB, AOLS, AFFY, and AOBI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
6/11/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
5/24/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
5/10/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
4/30/2025
89BIO stock logo
ETNB
89BIO
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/24/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
4/8/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/AN/A
AOBI
American Oriental Bioengineering
N/AN/AN/AN/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/AN/AN/AN/AN/A
89BIO stock logo
ETNB
89BIO
N/AN/AN/AN/A$3.34 per shareN/A
MYRX
Myrexis
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Affymax Inc. stock logo
AFFY
Affymax
N/AN/A0.00N/AN/AN/AN/AN/A
AOBI
American Oriental Bioengineering
N/AN/A0.00N/AN/AN/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A
89BIO stock logo
ETNB
89BIO
-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)
MYRX
Myrexis
N/AN/A0.00N/AN/AN/AN/AN/A

Latest MYRX, ETNB, AOLS, AFFY, and AOBI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
89BIO stock logo
ETNB
89BIO
-$0.49N/AN/AN/AN/AN/A
5/1/2025Q1 2025
89BIO stock logo
ETNB
89BIO
-$0.50-$0.49+$0.01-$0.49N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/A
AOBI
American Oriental Bioengineering
N/AN/AN/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/AN/AN/AN/A
89BIO stock logo
ETNB
89BIO
N/AN/AN/AN/AN/A
MYRX
Myrexis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/A
AOBI
American Oriental Bioengineering
N/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/AN/A
89BIO stock logo
ETNB
89BIO
0.06
18.03
18.03
MYRX
Myrexis
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Affymax Inc. stock logo
AFFY
Affymax
N/A
AOBI
American Oriental Bioengineering
N/A
AOLS
Aeolus Pharmaceuticals
N/A
89BIO stock logo
ETNB
89BIO
N/A
MYRX
Myrexis
N/A

Insider Ownership

CompanyInsider Ownership
Affymax Inc. stock logo
AFFY
Affymax
1.55%
AOBI
American Oriental Bioengineering
30.27%
AOLS
Aeolus Pharmaceuticals
66.60%
89BIO stock logo
ETNB
89BIO
2.80%
MYRX
Myrexis
0.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Affymax Inc. stock logo
AFFY
Affymax
4N/AN/ANot Optionable
AOBI
American Oriental Bioengineering
3,720N/AN/ANot Optionable
AOLS
Aeolus Pharmaceuticals
4N/AN/ANot Optionable
89BIO stock logo
ETNB
89BIO
40145.98 million141.90 millionOptionable
MYRX
Myrexis
1N/AN/ANot Optionable

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Affymax stock logo

Affymax OTCMKTS:AFFY

$0.0008 0.00 (0.00%)
As of 07/3/2025

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

American Oriental Bioengineering OTCMKTS:AOBI

$0.0005 0.00 (0.00%)
As of 07/3/2025

American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respiratory infections, mild pneumonia, bronchitis, and tonsillitis; and Cease Enuresis Soft Gel under the CE Gel brand to alleviate bedwetting. It also offers over-the-counter pharmaceutical products comprising Cease Enuresis Patch for the treatment of bedwetting and incontinence; Jinji Capsule for the treatment of endometritis, annexitis, and pelvic inflammations; Jinji Yimucao for the treatment of premenstrual syndrome (PMS) and other PMS and menopause-related symptoms; and Boke Nasal Spray for the treatment of sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis. In addition, the company provides various nutraceutical products, such as soybean peptide based drinks, tablets, powder, and instant coffee. Further, it is involved in the wholesale and retail of pharmaceutical and nutraceutical products. The company sells its products directly and through distributors to hospitals, clinics, pharmacies, supermarkets, fitness centers, specialty nutraceutical stores, and other retail outlets in the People's Republic of China. American Oriental Bioengineering, Inc. is headquartered in Beijing, China.

Aeolus Pharmaceuticals OTCMKTS:AOLS

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

89BIO stock logo

89BIO NASDAQ:ETNB

$10.14 +0.04 (+0.40%)
Closing price 07/3/2025 02:41 PM Eastern
Extended Trading
$10.14 -0.01 (-0.05%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Myrexis OTCMKTS:MYRX

$0.0002 0.00 (0.00%)
As of 07/3/2025

Myrexis, Inc. focuses on identifying, evaluating, and making financial investments in life sciences assets. The company was formerly known as Myriad Pharmaceuticals, Inc. and changed its name to Myrexis, Inc. in July 2010. Myrexis, Inc. is headquartered in New York, New York.